ATE416764T1 - Behandlungsmethoden während eingriffen in das gefässsystem - Google Patents

Behandlungsmethoden während eingriffen in das gefässsystem

Info

Publication number
ATE416764T1
ATE416764T1 AT03809618T AT03809618T ATE416764T1 AT E416764 T1 ATE416764 T1 AT E416764T1 AT 03809618 T AT03809618 T AT 03809618T AT 03809618 T AT03809618 T AT 03809618T AT E416764 T1 ATE416764 T1 AT E416764T1
Authority
AT
Austria
Prior art keywords
treatment methods
vascular system
vascular
methods during
during interventions
Prior art date
Application number
AT03809618T
Other languages
English (en)
Inventor
Roshantha Chandraratna
Yang-Dar Yuan
Tuong Dang
Sheng Loh
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE416764T1 publication Critical patent/ATE416764T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03809618T 2002-10-22 2003-10-21 Behandlungsmethoden während eingriffen in das gefässsystem ATE416764T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/278,770 US7105566B2 (en) 2002-10-22 2002-10-22 Methods of treatment during vascular procedures

Publications (1)

Publication Number Publication Date
ATE416764T1 true ATE416764T1 (de) 2008-12-15

Family

ID=32093435

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03809618T ATE416764T1 (de) 2002-10-22 2003-10-21 Behandlungsmethoden während eingriffen in das gefässsystem

Country Status (6)

Country Link
US (1) US7105566B2 (de)
EP (1) EP1558235B1 (de)
AT (1) ATE416764T1 (de)
AU (1) AU2003301673A1 (de)
DE (1) DE60325261D1 (de)
WO (1) WO2004037243A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070093536A1 (en) * 2003-12-01 2007-04-26 Yorimasa Suwa Target protein of antidiabetic and novel antidiabetic insuful corresponding thereto
JP2009510114A (ja) 2005-09-30 2009-03-12 ビテ ファーマシューティカルズ， インコーポレイテッド 特定のｒｘｒアゴニストによる癌治療
DK2026778T3 (en) * 2006-05-16 2019-01-07 Io Therapeutics Llc RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS
GB0915196D0 (en) * 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
US20130190395A1 (en) 2011-12-13 2013-07-25 Dartmouth College Autoimmune disorder treatment using rxr agonists
PL3368080T3 (pl) 2015-10-31 2023-09-11 Io Therapeutics, Inc. Leczenie zaburzeń układu nerwowego z zastosowaniem kombinacji agonistów rxr i hormonów tarczycy
SG11201807250PA (en) 2016-03-10 2018-09-27 Io Therapeutics Inc Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
CN115227826A (zh) 2016-03-10 2022-10-25 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
AU2018335393A1 (en) 2017-09-20 2020-04-02 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
JP7657223B2 (ja) * 2019-12-19 2025-04-04 オルファゲン ファーマシューティカルズ，インク． 炎症性疾患および男性避妊用ｒａｒアルファ化合物
IL308171A (en) * 2021-05-04 2023-12-01 Univ Minnesota Contraceptive compounds and methods
JP2024543621A (ja) 2021-12-07 2024-11-21 アイオー セラピューティクス インコーポレイテッド Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストおよびタキサンの使用
JP2024544223A (ja) 2021-12-07 2024-11-28 アイオー セラピューティクス インコーポレイテッド Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストの使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2102195T3 (es) 1992-12-28 1997-07-16 Eisai Co Ltd Derivados heterociclicos de acido carbonico que se fijan en receptores de retinoides.
US5648514A (en) 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5958954A (en) 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6218128B1 (en) * 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US6008204A (en) * 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
BR9610875A (pt) * 1995-10-06 1999-07-13 Ligand Pharm Inc Modulares rxr seletivos - dimeros e processos para seu uso
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
FR2753627B1 (fr) 1996-09-20 2003-02-21 Galderma Rech Dermatologique Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
CN1511519A (zh) * 1997-11-12 2004-07-14 - 2型t辅助细胞介导的免疫病的治疗
US6521641B1 (en) * 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
AU2001290816A1 (en) 2000-09-13 2002-03-26 Bristol-Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
US20020193403A1 (en) * 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
EP1427399A2 (de) * 2001-09-17 2004-06-16 The University Of Western Ontario Pan-antagonisten des retinoidrezeptors zur stimulierung der chondrogenese

Also Published As

Publication number Publication date
US7105566B2 (en) 2006-09-12
WO2004037243A3 (en) 2004-09-30
DE60325261D1 (de) 2009-01-22
EP1558235B1 (de) 2008-12-10
WO2004037243A2 (en) 2004-05-06
US20040077710A1 (en) 2004-04-22
EP1558235A2 (de) 2005-08-03
AU2003301673A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
DE60325261D1 (de) Behandlungsmethoden während eingriffen in das gefässsystem
Schaden et al. Shock wave therapy for acute and chronic soft tissue wounds: a feasibility study
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
DE60030889D1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
BRPI0810336A2 (pt) "método para tratar e/ou prevenir úlceras de pele em um indivíduo"
ATE524070T1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden
WO2006037088A3 (en) Method and device for extravascular intervention
ATE506019T1 (de) Kontrollierbare vorrichtung und kit zur behandlung von störungen des herzrhythmus- reguliersystems
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
CY1107352T1 (el) Προεγχειρητικη θεραπευτικη αγωγη μετεγχειρητικου πονου
DE60326548D1 (de) Verfahren zur verhütung oder behandlung von herzarrhythmie
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
EP1499190A4 (de) Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
DE69920015D1 (de) Verfahren zur induktion der herstellung von wachstumsfaktoren
DE60131100D1 (de) Verfahren zur behandlung bestimmter augenkrankheiten
RU2284155C1 (ru) Способ субфасциальной диссекции перфорантных вен голени при хронической венозной недостаточности
SU1061803A1 (ru) Способ лечени хронической ишемии конечности
EP4527316A4 (de) Vorrichtung zur behandlung der saphenavene und zugehörigen varizen sowie verfahren zu ihrer verwendung im menschlichen körper
UA29707A (uk) Спосіб відновлення кісткових тканин при переломах
RU2006106561A (ru) Способ лечения проксимального перидуоденита
UA37370A (uk) Спосіб прогнозування ефективності монотерапії антагоністами кальцію під час лікування гіпертонічної хвороби

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties